S&P 500   4,563.38 (-0.08%)
DOW   36,137.95 (+0.04%)
QQQ   386.28 (-0.26%)
AAPL   192.68 (-0.38%)
MSFT   368.72 (-1.02%)
META   319.00 (+0.22%)
GOOGL   130.40 (-0.45%)
AMZN   145.52 (-0.93%)
TSLA   244.69 (+2.50%)
NVDA   460.82 (-1.04%)
NIO   7.94 (+6.86%)
BABA   72.09 (-0.40%)
AMD   118.49 (+0.09%)
T   16.96 (-1.51%)
F   10.78 (+1.70%)
MU   73.52 (-0.23%)
CGC   0.69 (+3.06%)
GE   120.56 (+0.27%)
DIS   91.79 (+1.10%)
AMC   6.96 (-0.85%)
PFE   29.08 (-0.03%)
PYPL   59.97 (+3.54%)
XOM   98.63 (-1.80%)
S&P 500   4,563.38 (-0.08%)
DOW   36,137.95 (+0.04%)
QQQ   386.28 (-0.26%)
AAPL   192.68 (-0.38%)
MSFT   368.72 (-1.02%)
META   319.00 (+0.22%)
GOOGL   130.40 (-0.45%)
AMZN   145.52 (-0.93%)
TSLA   244.69 (+2.50%)
NVDA   460.82 (-1.04%)
NIO   7.94 (+6.86%)
BABA   72.09 (-0.40%)
AMD   118.49 (+0.09%)
T   16.96 (-1.51%)
F   10.78 (+1.70%)
MU   73.52 (-0.23%)
CGC   0.69 (+3.06%)
GE   120.56 (+0.27%)
DIS   91.79 (+1.10%)
AMC   6.96 (-0.85%)
PFE   29.08 (-0.03%)
PYPL   59.97 (+3.54%)
XOM   98.63 (-1.80%)
S&P 500   4,563.38 (-0.08%)
DOW   36,137.95 (+0.04%)
QQQ   386.28 (-0.26%)
AAPL   192.68 (-0.38%)
MSFT   368.72 (-1.02%)
META   319.00 (+0.22%)
GOOGL   130.40 (-0.45%)
AMZN   145.52 (-0.93%)
TSLA   244.69 (+2.50%)
NVDA   460.82 (-1.04%)
NIO   7.94 (+6.86%)
BABA   72.09 (-0.40%)
AMD   118.49 (+0.09%)
T   16.96 (-1.51%)
F   10.78 (+1.70%)
MU   73.52 (-0.23%)
CGC   0.69 (+3.06%)
GE   120.56 (+0.27%)
DIS   91.79 (+1.10%)
AMC   6.96 (-0.85%)
PFE   29.08 (-0.03%)
PYPL   59.97 (+3.54%)
XOM   98.63 (-1.80%)
S&P 500   4,563.38 (-0.08%)
DOW   36,137.95 (+0.04%)
QQQ   386.28 (-0.26%)
AAPL   192.68 (-0.38%)
MSFT   368.72 (-1.02%)
META   319.00 (+0.22%)
GOOGL   130.40 (-0.45%)
AMZN   145.52 (-0.93%)
TSLA   244.69 (+2.50%)
NVDA   460.82 (-1.04%)
NIO   7.94 (+6.86%)
BABA   72.09 (-0.40%)
AMD   118.49 (+0.09%)
T   16.96 (-1.51%)
F   10.78 (+1.70%)
MU   73.52 (-0.23%)
CGC   0.69 (+3.06%)
GE   120.56 (+0.27%)
DIS   91.79 (+1.10%)
AMC   6.96 (-0.85%)
PFE   29.08 (-0.03%)
PYPL   59.97 (+3.54%)
XOM   98.63 (-1.80%)

9 Meters Biopharma (NMTR) News Today

Compare
Today's Range
N/A
50-Day Range
$0.00
▼
$0.02
52-Week Range
N/A
Volume
11,067 shs
Average Volume
315,915 shs
Market Capitalization
$1.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.70
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
bizjournals.com logoDeal reached to sell some assets of bankrupt Raleigh firm
bizjournals.com - November 8 at 7:34 PM
finance.yahoo.com logo9 Meters Biopharma, Inc. (NMTRQ)
finance.yahoo.com - November 7 at 7:35 PM
investing.com logo9 Meters Biopharma Inc (NMTRQ)
investing.com - October 17 at 12:10 PM
fool.com logo9 Meters Biopharma (OTC: NMTR.Q)
fool.com - August 16 at 5:48 PM
bizjournals.com logoRaleigh firm joins worrying trend of bankruptcies for drugmakers
bizjournals.com - July 18 at 8:47 PM
reuters.com logoDrug developer 9 Meters Biopharma files for bankruptcy protection
reuters.com - July 18 at 3:42 PM
finance.yahoo.com logoWhy Are 9 Meters Biopharma Shares Nosediving Today?
finance.yahoo.com - July 18 at 3:42 PM
bizjournals.com logoTemperato resigns as CEO of Raleigh drugmaker
bizjournals.com - May 30 at 11:34 PM
finance.yahoo.com logo9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
finance.yahoo.com - May 30 at 1:33 PM
fool.com logo9 Meters Biopharma (NASDAQ: NMTR)
fool.com - May 28 at 12:31 AM
uk.finance.yahoo.com logoNMTR - 9 Meters Biopharma, Inc.
uk.finance.yahoo.com - May 25 at 11:56 PM
msn.com logoCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral Recommendation
msn.com - May 19 at 8:44 AM
finance.yahoo.com logo9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
finance.yahoo.com - May 15 at 7:40 PM
finance.yahoo.com logo9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
finance.yahoo.com - April 5 at 8:59 AM
bizjournals.com logoWhy this Raleigh pharma just cut half its workforce
bizjournals.com - March 30 at 8:33 AM
finance.yahoo.com logo9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
finance.yahoo.com - March 28 at 10:42 AM
seekingalpha.com logoNMTR 9 Meters Biopharma, Inc.
seekingalpha.com - March 25 at 11:55 PM
benzinga.com logo9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and Forecast
benzinga.com - March 22 at 12:34 AM
bizjournals.com logoRaleigh pharma raises $5M as phase 3 study begins
bizjournals.com - March 16 at 9:51 AM
finance.yahoo.com logo9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - March 15 at 6:38 PM
finance.yahoo.com logo9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
finance.yahoo.com - March 14 at 9:25 AM
finance.yahoo.com logo9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
finance.yahoo.com - March 7 at 7:36 PM
theguardian.com logoSuppliers told to remove prepayment meters that were wrongly force-fitted
theguardian.com - February 23 at 11:57 PM
finance.yahoo.com logo9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
finance.yahoo.com - January 31 at 12:55 PM
theguardian.com logoLabour calls for halt to ‘shameful’ forced installation of prepayment meters
theguardian.com - January 17 at 5:46 PM
theguardian.com logoMPs warn over forced prepayment meters as cold weather returns
theguardian.com - January 15 at 12:57 AM
news.yahoo.com logoEnergy bills: 'I was forced onto a prepayment meter'
news.yahoo.com - January 14 at 12:48 AM
thetimes.co.uk logoMillions of families forced to have prepayment gas and electric meters
thetimes.co.uk - January 14 at 12:48 AM
finance.yahoo.com logo9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
finance.yahoo.com - November 29 at 1:28 PM
finance.yahoo.com logo9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
finance.yahoo.com - November 14 at 9:12 AM
finance.yahoo.com logo9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
finance.yahoo.com - November 8 at 10:36 AM
finance.yahoo.com logo9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting
finance.yahoo.com - October 24 at 10:54 AM
bizjournals.com logo9 Meters Biopharma triggers reverse stock split to maintain Nasdaq listing
bizjournals.com - October 18 at 8:37 AM
finance.yahoo.com logo9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
finance.yahoo.com - October 18 at 8:37 AM
finance.yahoo.com logo9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
finance.yahoo.com - October 17 at 9:18 AM
seekingalpha.com logo9 Meters Biopharma gains after mid-stage data for short bowel syndrome drug
seekingalpha.com - September 27 at 8:32 AM
finance.yahoo.com logo9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome
finance.yahoo.com - September 26 at 5:31 PM
finance.yahoo.com logo9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 6 at 10:15 AM
finance.yahoo.com logo9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
finance.yahoo.com - September 1 at 8:27 AM
finance.yahoo.com logo9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
finance.yahoo.com - August 31 at 10:16 AM
uk.finance.yahoo.com logo9 Meters Biopharma, Inc. (NMTR)
uk.finance.yahoo.com - August 13 at 7:29 PM
finance.yahoo.com logo9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
finance.yahoo.com - July 6 at 9:44 AM
bizjournals.com logoRaleigh drugmaker shifts focus after trial setback
bizjournals.com - July 5 at 7:51 AM
seekingalpha.com logo9 Meters stock falls despite drug showing promise in short bowel syndrome trial
seekingalpha.com - June 30 at 11:56 AM
seekingalpha.com logo9 Meters gets $70M debt facility for phase 3 development of short bowel syndrome drug
seekingalpha.com - June 30 at 11:56 AM
finance.yahoo.com logo9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
finance.yahoo.com - June 30 at 11:56 AM
finance.yahoo.com logo9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
finance.yahoo.com - June 30 at 11:56 AM
finance.yahoo.com logoRaleigh pharma sees stock tumble after stopping trial. Now what?
finance.yahoo.com - June 22 at 7:14 AM
seekingalpha.com logo9 Meters stock slumps 54% as phase 3 Celiac disease trial of larazotide gets axed
seekingalpha.com - June 21 at 4:14 PM
finance.yahoo.com logoWhy Are 9 Meters Biopharma Shares Plunging Today?
finance.yahoo.com - June 21 at 4:14 PM
Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.



NMTR Media Mentions By Week

NMTR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NMTR
News Sentiment
▼
0.00

0.43
▲
Average
Medical
News Sentiment

NMTR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NMTR Articles
This Week
▼
0

0
▲
NMTR Articles
Average Week

Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:NMTR) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -